JP2009513562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009513562A5 JP2009513562A5 JP2008521463A JP2008521463A JP2009513562A5 JP 2009513562 A5 JP2009513562 A5 JP 2009513562A5 JP 2008521463 A JP2008521463 A JP 2008521463A JP 2008521463 A JP2008521463 A JP 2008521463A JP 2009513562 A5 JP2009513562 A5 JP 2009513562A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- salt
- alkoxy
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 42
- 150000001875 compounds Chemical class 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 28
- 125000003545 alkoxy group Chemical group 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000006239 protecting group Chemical group 0.000 claims 5
- 208000005176 Hepatitis C Diseases 0.000 claims 4
- 238000010511 deprotection reaction Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000005022 packaging material Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 238000007363 ring formation reaction Methods 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- -1 carbamoyloxy Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 108010069514 Cyclic Peptides Proteins 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 claims 1
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000006462 rearrangement reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 0 CC(*)N(C)*1CC1 Chemical compound CC(*)N(C)*1CC1 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73001105P | 2005-10-26 | 2005-10-26 | |
| US60/730,011 | 2005-10-26 | ||
| US75120405P | 2005-12-19 | 2005-12-19 | |
| US60/751,204 | 2005-12-19 | ||
| PCT/JP2006/321924 WO2007049803A1 (en) | 2005-10-26 | 2006-10-26 | New cyclic peptide compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009513562A JP2009513562A (ja) | 2009-04-02 |
| JP2009513562A5 true JP2009513562A5 (https=) | 2009-11-19 |
| JP5218051B2 JP5218051B2 (ja) | 2013-06-26 |
Family
ID=37847219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008521463A Expired - Fee Related JP5218051B2 (ja) | 2005-10-26 | 2006-10-26 | 新規環状ペプチド化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7872097B2 (https=) |
| EP (1) | EP1957518B1 (https=) |
| JP (1) | JP5218051B2 (https=) |
| KR (1) | KR101273681B1 (https=) |
| CN (1) | CN101305019B (https=) |
| AU (1) | AU2006306974B2 (https=) |
| BR (1) | BRPI0617781A2 (https=) |
| CA (1) | CA2623898C (https=) |
| ES (1) | ES2557477T3 (https=) |
| IL (1) | IL190286A0 (https=) |
| NO (1) | NO20082354L (https=) |
| PL (1) | PL1957518T3 (https=) |
| PT (1) | PT1957518E (https=) |
| RU (1) | RU2423377C2 (https=) |
| TW (1) | TWI391403B (https=) |
| WO (1) | WO2007049803A1 (https=) |
| ZA (1) | ZA200803525B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100017547A (ko) | 2007-05-02 | 2010-02-16 | 아스텔라스세이야쿠 가부시키가이샤 | 신규 시클릭 펩티드 화합물 |
| CN102164947A (zh) * | 2008-09-24 | 2011-08-24 | 安斯泰来制药有限公司 | 肽化合物及其制备方法 |
| KR20110111321A (ko) * | 2009-01-30 | 2011-10-10 | 이난타 파마슈티칼스, 인코포레이티드 | Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체 |
| US8481483B2 (en) | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| SG176085A1 (en) * | 2009-05-15 | 2011-12-29 | Stichting Nl Kanker Inst | Lysine compounds and their use in site- and chemoselective modification of peptides and proteins |
| US8349312B2 (en) | 2009-07-09 | 2013-01-08 | Enanta Pharmaceuticals, Inc. | Proline substituted cyclosporin analogues |
| US8367053B2 (en) | 2009-07-09 | 2013-02-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US8685917B2 (en) | 2009-07-09 | 2014-04-01 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| WO2011082289A1 (en) * | 2009-12-30 | 2011-07-07 | Scynexis Inc. | Cyclosporine analogues |
| JP2015529206A (ja) | 2012-08-25 | 2015-10-05 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Ｇａｐｄｈカスケードインヒビター化合物ならびに使用の方法および精神病を含むストレス誘導障害の処置 |
| EP2900684A2 (en) | 2012-09-29 | 2015-08-05 | Novartis AG | Cyclic peptides and use as medicines |
| WO2014085623A1 (en) | 2012-11-28 | 2014-06-05 | Enanta Pharmaceuticals, Inc. | Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues |
| JP2016538317A (ja) | 2013-08-26 | 2016-12-08 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎を防止または治療するための新規シクロスポリン類似体 |
| US9669095B2 (en) | 2014-11-03 | 2017-06-06 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis C infection |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05271267A (ja) * | 1991-04-23 | 1993-10-19 | Fujisawa Pharmaceut Co Ltd | Ｆｒ９０１４５９物質、その製法及び用途 |
| AU759480B2 (en) | 1998-07-01 | 2003-04-17 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
| AU2001295966A1 (en) * | 2000-10-19 | 2002-04-29 | Fujisawa Pharmaceutical Co. Ltd. | Cell damage inhibitor |
| CN100344648C (zh) * | 2001-10-19 | 2007-10-24 | 伊索泰克尼卡股份有限公司 | 环孢菌素类似物混合物及其在制备免疫调节剂中的用途 |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| JP2007015926A (ja) * | 2003-10-06 | 2007-01-25 | Fujisawa Pharmaceut Co Ltd | Ｃ型肝炎治療剤 |
| DK1793844T3 (da) | 2004-10-01 | 2011-03-21 | Debiopharm Sa | Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion |
| SI1802650T1 (sl) | 2004-10-01 | 2012-03-30 | Scynexis Inc | Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c |
| ES2314731T3 (es) * | 2004-11-22 | 2009-03-16 | Astellas Pharma Inc. | Analogo de ciclosporina. |
-
2006
- 2006-10-26 PT PT68228444T patent/PT1957518E/pt unknown
- 2006-10-26 US US12/083,551 patent/US7872097B2/en active Active
- 2006-10-26 TW TW095139941A patent/TWI391403B/zh not_active IP Right Cessation
- 2006-10-26 WO PCT/JP2006/321924 patent/WO2007049803A1/en not_active Ceased
- 2006-10-26 ES ES06822844.4T patent/ES2557477T3/es active Active
- 2006-10-26 BR BRPI0617781-6A patent/BRPI0617781A2/pt not_active Application Discontinuation
- 2006-10-26 PL PL06822844T patent/PL1957518T3/pl unknown
- 2006-10-26 CA CA2623898A patent/CA2623898C/en not_active Expired - Fee Related
- 2006-10-26 KR KR1020087012431A patent/KR101273681B1/ko not_active Expired - Fee Related
- 2006-10-26 AU AU2006306974A patent/AU2006306974B2/en not_active Ceased
- 2006-10-26 JP JP2008521463A patent/JP5218051B2/ja not_active Expired - Fee Related
- 2006-10-26 RU RU2008116674/04A patent/RU2423377C2/ru not_active IP Right Cessation
- 2006-10-26 CN CN2006800390294A patent/CN101305019B/zh not_active Expired - Fee Related
- 2006-10-26 EP EP06822844.4A patent/EP1957518B1/en active Active
-
2008
- 2008-03-19 IL IL190286A patent/IL190286A0/en unknown
- 2008-04-22 ZA ZA2008/03525A patent/ZA200803525B/en unknown
- 2008-05-23 NO NO20082354A patent/NO20082354L/no not_active Application Discontinuation
-
2010
- 2010-07-21 US US12/840,488 patent/US8252895B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2881395T3 (es) | Composiciones y métodos para inhibir la actividad de la arginasa | |
| AU2024200147B2 (en) | Exatecan derivatives, linker-payloads, and conjugates and thereof | |
| ES2354282T3 (es) | Análogos peptídicos inhibidores de la hepatitis c. | |
| TWI440641B (zh) | 蛋白酶體抑制劑 | |
| US20240166652A1 (en) | Modulators of the integrated stress pathway | |
| EP1910378B1 (en) | Hepatitis c inhibitor peptide analogs | |
| JP2009513562A5 (https=) | ||
| AU2015243379B2 (en) | Tubulysin derivatives | |
| JP6419072B2 (ja) | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 | |
| US20210230195A1 (en) | Prodrug modulators of the integrated stress pathway | |
| TWI853790B (zh) | 細胞穿透肽序列 | |
| EP3261443B1 (en) | Desacetoxytubulysin h and analogs thereof | |
| CN112204006A (zh) | 整合应激通路的调节剂 | |
| EA034759B1 (ru) | Пролекарства рилузола и их применение | |
| IL300589A (en) | Peptides that function as antiviral agents | |
| CN115947681A (zh) | 整合应激通路的调节剂 | |
| EP3560926B1 (en) | 6-amino-7,9-dihydro-8h-purin-8-one compounds as brk inhibitors | |
| CN105849092A (zh) | 作为免疫调节剂的1，3，4-*二唑和1，3，4-噻二唑衍生物 | |
| ES2888800T3 (es) | Procedimiento mejorado para la preparación de carfilzomib o sales farmacéuticamente aceptables del mismo | |
| TW200826938A (en) | Hepatitis C virus inhibitors | |
| JP7100782B2 (ja) | 複素環によって構成されるトリペプチドエポキシケトン化合物、並びにその作製方法及び使用 | |
| TW201119667A (en) | Bismacrocyclic compounds as hepatitis C virus inhibitors | |
| TW200815478A (en) | Organic compounds and their uses | |
| ES2463820T3 (es) | Derivado de imidazotiazol que tiene estructura de anillo de prolina | |
| RU2008116674A (ru) | Новые циклические пептидные соединения |